secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001193125-25-025524
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor
--------------------------------------------------------------------------------

- Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.
- He will also cease serving on the Science and Technology Committee of the board.
- He will continue as a strategic advisor to leadership, focusing on advancing clinical development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/0001193125-25-025524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/d927492d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-025524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer